Literature DB >> 1902660

Lack of effectiveness of tissue plasminogen activator 20 or more days after vitrectomy.

J C Folk, J M Hershey, M B Rivers.   

Abstract

Mesh:

Substances:

Year:  1991        PMID: 1902660     DOI: 10.1001/archopht.1991.01080050020010

Source DB:  PubMed          Journal:  Arch Ophthalmol        ISSN: 0003-9950


× No keyword cloud information.
  6 in total

1.  Recombinant tissue plasminogen activator following paediatric cataract surgery.

Authors:  J S Mehta; G G Adams
Journal:  Br J Ophthalmol       Date:  2000-09       Impact factor: 4.638

2.  The use of tissue plasminogen activator in postvitrectomy cases.

Authors:  C Koutsandrea; M Apostolopoulos; P Theodossiadis
Journal:  Int Ophthalmol       Date:  1993-04       Impact factor: 2.031

Review 3.  Alteplase. A reappraisal of its pharmacology and therapeutic use in vascular disorders other than acute myocardial infarction.

Authors:  A J Wagstaff; J C Gillis; K L Goa
Journal:  Drugs       Date:  1995-08       Impact factor: 9.546

4.  Recombinant tissue plasminogen activator injected into the vitreous cavity may penetrate the retinal veins of a porcine model of vascular occlusion.

Authors:  T H Mahmoud; Y-W Peng; A D Proia; M Davidson; V A Deramo; S Fekrat
Journal:  Br J Ophthalmol       Date:  2006-03-15       Impact factor: 4.638

5.  Recombinant tissue plasminogen activator in cases with fibrin formation after cataract surgery: a prospective randomised multicentre study.

Authors:  A Heiligenhaus; B Steinmetz; R Lapuente; P Krallmann; C Althaus; W K Steinkamp; B Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

6.  Use of recombinant tissue plasminogen activator for treatment of recalcitrant anterior uveitis: A case series.

Authors:  Sylves Patrick; Chan Hui-Tze; Wan Hitam Wan-Hazabbah; Embong Zunaina; Yaakub Azhany; Ahmad Tajudin Liza-Sharmini
Journal:  J Taibah Univ Med Sci       Date:  2018-04-06
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.